Back to results
US 2025/0144140 A1Published application
Methods for allogeneic hematopoietic stem cell transplantation
AssigneeOrca Biosystems, Inc.
InventorsScott Killian, Scott McClellan, Amy Putnam, Nathaniel Fernhoff
Life of this patent
Estimating the term…
Abstract
Various embodiments of the present disclosure provide therapeutic compositions and associated methods for improved hematopoietic stem cell transplantations, including methods to enhance protection from graft versus host disease while maintaining effective immune responses such as graft versus tumor immune responses.
Claims21
A multi-component cellular therapy product comprising:
- a) a first single dose transfer bag comprising a first population of isolated CD45+ cells comprising a dose of approximately 1.0×105 to approximately 1.0×108 CD34+ hematopoietic stem and progenitor cells (HSPCs) per kilogram of body weight of a human subject receiving the product, wherein the first population of CD45+ cells is formulated with an excipient at a neutral pH;
- b) a second single dose transfer bag comprising a second population of isolated CD45+ cells comprising a dose of approximately 1.0×105 to approximately 2.0×107 fresh CD4+CD25+CD127dim regulatory T cells (Tregs) per kilogram of body weight of the human subject receiving the product, wherein the second population of isolated CD45+ cells is formulated with an excipient at a neutral pH, optionally wherein the first single dose transfer bag and the second single dose transfer bag are the same transfer bag;
- and
- c) a third single dose transfer bag comprising a third population of isolated CD45+ cells comprising a dose of approximately 1.0×105 to approximately 4.0×107 conventional CD3+ T cells (Tcons) per kilogram of body weight of the human subject receiving the product, wherein the third population of isolated CD45+ cells is formulated with an excipient at a neutral pH, wherein the excipient comprises one more cryoprotectants.
1 more element
(canceled)
A method of preparing a multi-component cellular therapy product comprising:
- a) obtaining an HSPC-mobilized peripheral blood apheresis sample from a donor that is allogeneic with respect to a human subject receiving the product;
- and
- b) selecting from the apheresis sample a first sample comprising from approximately 1.0×105 to approximately 1.0×108 CD34+ hematopoietic stem and progenitor cells (HSPCs) per kilogram of body weight of the human subject receiving the product, a second sample comprising from approximately 1.0×105 to approximately 2.0×107 CD4+CD25+CD127dim regulatory T cells (Tregs) per kilogram of body weight of the human subject receiving the product, and a third sample comprising from approximately 1.0×105 to approximately 4.0×107 conventional CD3+ T cells (Tcons) per kilogram of body weight of the human subject receiving the product, wherein the multi-component cellular therapy product comprises the Tcons, the HSPCs, and the Tregs, wherein the HSPCs are selected by sorting the first sample with one or more ISPs specific for CD34 and selecting a CD34-enriched population, wherein the Tregs are selected by soring the second sample with one or more ISPs specific for CD25, one or more ISPs specific for CD4, and/or one or more ISPs specific for CD127, and selecting the CD4+ and CD127dim cell population.
Dependencies are inferred from the claim text.